CoChat

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study. METHODS DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centres in eight countries. Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncology Group performance status of 0-2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via intravenous infusion every 3 weeks on day 1 of each cycle until disease progression or unacceptable toxicity. The intention-to-treat population comprised all randomised patients, regardless of treatment administration. The safety population comprised all patients who received at least one dose of belantamab mafodotin. The primary outcome was the proportion of randomly assigned patients in the intention-to-treat population who achieved an overall response, as assessed by an independent review committee. This study is registered with ClinicalTrials.gov, NCT03525678, and is ongoing. FINDINGS Between June 18, 2018, and Jan 2, 2019, 293 patients were screened and 196 were included in the intention-to-treat population (97 in the 2·5 mg/kg cohort and 99 in the 3·4 mg/kg cohort). As of June 21, 2019 (the primary analysis data cutoff date), 30 (31%; 97·5% CI 20·8-42·6) of 97 patients in the 2·5 mg/kg cohort and 34 (34%; 23·9-46·0) of 99 patients in the 3·4 mg/kg cohort achieved an overall response. The most common grade 3-4 adverse events in the safety population were keratopathy (in 26 [27%] of 95 patients in the 2·5 mg/kg cohort and 21 [21%] of 99 patients in the 3·4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anaemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients in the 2·5 mg/kg cohort and 47 (47%) of 99 in the 3·4 mg/kg cohort reported serious adverse events. Two deaths were potentially treatment related (one case of sepsis in the 2·5 mg/kg cohort and one case of haemophagocytic lymphohistiocytosis in the 3·4 mg/kg cohort). INTERPRETATION Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma. FUNDING GlaxoSmithKline.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30788-0

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 28 references

Cited by

See all 827

Metadata

Authors
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P., & Cohen, A. D.
Affiliations
  • Emory University (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Maryland, Baltimore (US)
  • Princess Margaret Cancer Centre (CA)
  • Winship Cancer Institute (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Kansas (US)
  • University of Wisconsin–Madison (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Huntsman Cancer Institute (US)
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
  • Universitätsklinikum Tübingen (DE)
  • Hospices Civils de Lyon (FR)
  • University of Washington (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Universitätsklinikum Würzburg (DE)
  • Levine Cancer Institute (US)
  • Medical College of Wisconsin (US)
  • Moffitt Cancer Center (US)
  • The University of Melbourne (AU)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • GlaxoSmithKline (United States) (US)
  • University College London Hospitals NHS Foundation Trust (GB)
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • Dana-Farber Cancer Institute (US)
  • Abramson Cancer Center (US)
Corresponding author
Lonial, Sagar
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-02
Volume
21
Issue
2
Pages
207-221
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2995934717
Cited by
812
References
30
Citations by year
2026: 60 · 2025: 89 · 2024: 89 · 2023: 151 · 2022: 153 · 2021: 173 · 2020: 92
FWCI
73.72
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute for Health and Care Research
  • UCLH Biomedical Research Centre
  • GlaxoSmithKline
  • Seattle Genetics
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
belantamab mafodotin, relapsed/refractory multiple myeloma, BCMA, antibody-drug conjugates, overall response rate, progression-free survival, treatment safety, dose escalation, anti-CD38 monoclonal antibody, heavily pretreated patients, immunomodulators, proteasome inhibitors, cytogenetic features
MeSH terms
Antineoplastic Agents, Immunological, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Multiple Myeloma, Time Factors, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30788-0
The paper
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., . . . Cohen, A. D. (2020). Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30788-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.